Exelixis develops and commercializes oncology therapies, primarily small‑molecule targeted drugs such as cabozantinib, and generates recurring commercial revenue from marketed treatments across global markets.
Financials show a recovery and steady expansion: revenue rose from $425.2 million in CY2024Q1 to $628.7 million in CY2026Q2, with recent year‑over‑year growth near 10% in the last two reported quarters. Quarterly GAAP diluted EPS increased from $0.12 in CY2024Q1 to $0.82 in CY2026Q2, reflecting improving reported profitability; the company’s metrics show steady gains, but revenue and EPS are flagged as not accelerating.
Technically and in leadership screens Exelixis rates as a theme leader: the stock trades above its 50‑ and 200‑day averages, passed all seven trend checks and sits in a Weinstein Stage 2 continuation, and it has outperformed the S&P by roughly 39.2% over 12 months. The leader‑selection score is 69 with a theme score of 9, indicating constructive volume and accumulation profiles alongside the commercial recovery.
Why now
The timing rests on an established uptrend and recent company disclosures: the stock is about 0.2% below its 52‑week high, relative strength and a positive up/down volume ratio point to continuing accumulation, and the company filed a 10‑Q on 2026‑08‑05 with subsequent 8‑Ks through 2026‑08‑31; at the same time the technical setup is labeled a watch, so the near‑term opportunity is contingent on a verified breakout or a fresh short‑term add signal.
The setup
Last close was $59.01 (2026‑09‑04), above the nine‑ and 21‑day EMAs (56.96 and 55.61), the 50‑day SMA (55.05) and the 200‑day SMA (47.65); RSI is 64.49, distance from the nine‑day EMA is about 3.6%, and the 50‑day up/down volume ratio is 1.43. The trend is constructive, but entry‑readiness is 'watch' with no verified pivot or fresh breakout recorded in the past 110 sessions.
Revenue trajectory
Full-year revenue with year-over-year growth. Solid bars are calendar-year actuals from SEC EDGAR filings (XBRL); dashed bars are analyst consensus via Yahoo Finance (18 analysts), which is published two fiscal years out.Earnings trajectory
Solid bars are quarterly GAAP diluted EPS from SEC EDGAR filings. Dashed bars are analyst consensus, which is typically adjusted (non-GAAP). The two are measured differently, so a step between the last actual and the first estimate usually reflects that change in basis rather than a change in the business.Analyst full-year EPS consensus (typically adjusted): FY'26E $3.58 (+16%) · FY'27E $4.26 (+19%) — 18 analysts
Risks
Key risks include continued reliance on commercial product performance and competitive or regulatory setbacks that could quickly dent revenue; the company’s growth is steady but not accelerating, so a slowdown could pressure sentiment; and institutional sponsorship is modest at roughly 1.1% of shares, which could leave the stock more sensitive to short‑term flows and headline risk.
Framework fit
CANSLIM
7/7- CCurrent quarterly GAAP EPS growth ≥ 25%+26%✓
- AAnnual GAAP EPS growth ≥ 25%+58%✓
- NNew highs — within 15% of 52-week high-0.2%✓
- SSupply/demand — up-day volume leads1.43x✓
- LLeader — outperforming the S&P 500+28% 6m✓
- IInstitutional sponsorshipmodel score 6/10✓
- MMarket in a confirmed uptrendConfirmed uptrend✓
Minervini Trend Template
7/7Stage 2 confirmation checklist: price versus rising long-term moving averages and the 52-week range.
Weinstein Stage
Established uptrend: price is above a rising 30-week proxy, with the 200-day line used as a separate confirmation.